Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
in vivo CAR-T
Biotech
J&J pays Sail $785M, securing option on in vivo CAR-T buyout
J&J is cruising deeper into in vivo CAR-T waters, paying $785 million upfront to strike a deal that gives it the option to acquire Sail Biomedicines.
Nick Paul Taylor
Jul 30, 2026 5:30am
Moderna enters in vivo CAR-T with autoimmune asset
Jun 26, 2026 9:00am
ASCO: Lilly's faith in Kelonia rewarded with ‘nutty’ CAR-T data
May 31, 2026 8:00am
Create Medicines fashions $122M raise for in vivo CAR-T dreams
May 14, 2026 9:42am
Novartis CEO ‘continuing to evaluate’ in vivo CAR-Ts
Apr 28, 2026 3:21am
After Lilly-Kelonia deal, are any in vivo biotechs left to buy?
Apr 24, 2026 9:30am
